Signs that Nordic Nanovector’s Paradigm trial was on its last legs were clear last month when the company initiated a comprehensive review after enrollment ground to a halt.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,